Selenium and antioxidant levels in children with intractable epilepsy receiving ketogenic diet

被引:0
作者
Omnia F. El-Rashidy
Mai M. Youssef
Yasmin G. Elgendy
Manal A. Mohsen
Safaa M. Morsy
Sarah A. Dawh
Khaled Saad
机构
[1] Ain Shams University,Department of Pediatrics, Faculty of Medicine
[2] National Research Centre,Child Health Department
[3] National Research Centre,Medical Biochemistry Department
[4] Assiut University,Department of Pediatrics, Faculty of Medicine
来源
Acta Neurologica Belgica | 2020年 / 120卷
关键词
Intractable epilepsy; Ketogenic diet; Selenium; Antioxidant;
D O I
暂无
中图分类号
学科分类号
摘要
Ketogenic diet is a high-fat, low-carbohydrate, and adequate-protein diet. It is well-established as a treatment option for drug-resistant childhood epilepsies. Our study aimed to evaluate Selenium levels and oxidative stress in children receiving ketogenic diet for intractable seizures for 6 months. This is a comparative case–control study included 90 children under 6 years age. They were subdivided into three groups. Group I: Thirty patients with drug-resistant epilepsy under antiepileptic drugs only. Group II: Thirty patients with drug-resistant epilepsy under treatment with ketogenic diet for 6 months and antiepileptic drugs. Group III: Thirty age and sex-matched healthy children as controls. Full history taking with special emphasis on severity and frequency of seizures, neurological examination, anthropometric measurements and laboratory analysis for serum Malonaldehyde, and total antioxidant capacity and Selenium were done for all participants. The frequency and severity of seizures were significantly lower in group II receiving ketogenic diet than group I on antiepileptic drugs only. Selenium levels were significantly lower in epileptic patients in comparison to controls. However, it was markedly lower in the ketogenic diet group. Malonaldehyde levels were significantly higher in epileptic children in comparison to controls, with lower values among ketogenic diet group when compared to patients on antiepileptic drugs only. Total antioxidant capacity levels were significantly lower in epileptic patients in comparison to controls, with higher values among ketogenic diet group as compared to epileptic patients on pharmacological treatment. Ketogenic diet is an effective treatment for refractory epilepsy for its anti-epileptic mechanism. It also may exert antioxidant effects. The nutrient content of the ketogenic diet may not meet the recommended daily allowance for selenium. So, this should be taken into consideration for supplementation of minerals in adequate amounts for patients receiving this diet.
引用
收藏
页码:375 / 380
页数:5
相关论文
共 104 条
[1]  
Saad K(2014)Childhood epilepsy: an update on diagnosis and management Am J Neurosci. 5 36-51
[2]  
Devi PU(2008)Seizures, antiepileptics, antioxidants and oxidative stress: an insight for researchers Expert Opin Pharmacother 9 3169-3177
[3]  
Manocha A(2015)A randomized, double-blind, placebo-controlled clinical trial of the efficacy of treatment with zinc in children with intractable epilepsy Funct Neurol 30 181-185
[4]  
Vohora D(2010)Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies Epilepsia. 51 1069-1077
[5]  
Saad K(2017)Ketogenic diet versus gluten free casein free diet in autistic children: a case-control study Metab Brain Dis. 32 1935-1941
[6]  
El-Houfey AA(2014)Neurobiochemical mechanisms of a ketogenic diet in refractory epilepsy Clinics. 69 699-705
[7]  
Abd El-Hamed MA(2012)Ketogenic diet: rapid onset of selenium deficiency-induced cardiac decompensation Pediatr Cardiol 33 834-838
[8]  
El-Asheer OM(2014)Trace element, oxidant, and antioxidant enzyme values in blood of children with refractory epilepsy Int J Neurosci 124 181-767
[9]  
Al-Atram AA(2016)Antioxidative–oxidative balance in epilepsy patients on antiepileptic therapy: a prospective case–control study Neurol Sci 37 763-344
[10]  
Tawfeek MS(2015)Ketogenic diet in epileptic children: impact on lipoproteins and oxidative stress Nutr Neurosci. 18 337-876